367 related articles for article (PubMed ID: 31273347)
1. Bromodomains: a new target class for drug development.
Cochran AG; Conery AR; Sims RJ
Nat Rev Drug Discov; 2019 Aug; 18(8):609-628. PubMed ID: 31273347
[TBL] [Abstract][Full Text] [Related]
2. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
3. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
4. The making of I-BET762, a BET bromodomain inhibitor now in clinical development.
Zhao Y; Yang CY; Wang S
J Med Chem; 2013 Oct; 56(19):7498-500. PubMed ID: 24107192
[TBL] [Abstract][Full Text] [Related]
5. Advancements in the Development of non-BET Bromodomain Chemical Probes.
Clegg MA; Tomkinson NCO; Prinjha RK; Humphreys PG
ChemMedChem; 2019 Feb; 14(4):362-385. PubMed ID: 30624862
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
7. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
[TBL] [Abstract][Full Text] [Related]
8. Recent progress and structural analyses of domain-selective BET inhibitors.
Divakaran A; Harki DA; Pomerantz WCK
Med Res Rev; 2023 Jul; 43(4):972-1018. PubMed ID: 36971240
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G
Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323
[TBL] [Abstract][Full Text] [Related]
10. Binding Assays for Bromodomain Proteins: Their Utility in Drug Discovery in Oncology and Inflammatory Disease.
Zolotarjova NI; Wynn R
Curr Protoc Pharmacol; 2018 Mar; 80(1):3.16.1-3.16.14. PubMed ID: 30040205
[TBL] [Abstract][Full Text] [Related]
11. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
Mirguet O; Gosmini R; Toum J; Clément CA; Barnathan M; Brusq JM; Mordaunt JE; Grimes RM; Crowe M; Pineau O; Ajakane M; Daugan A; Jeffrey P; Cutler L; Haynes AC; Smithers NN; Chung CW; Bamborough P; Uings IJ; Lewis A; Witherington J; Parr N; Prinjha RK; Nicodème E
J Med Chem; 2013 Oct; 56(19):7501-15. PubMed ID: 24015967
[TBL] [Abstract][Full Text] [Related]
12. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
[TBL] [Abstract][Full Text] [Related]
13. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
14. Targeting bromodomains: epigenetic readers of lysine acetylation.
Filippakopoulos P; Knapp S
Nat Rev Drug Discov; 2014 May; 13(5):337-56. PubMed ID: 24751816
[TBL] [Abstract][Full Text] [Related]
15. A patent review of BRD4 inhibitors (2013-2019).
Lu T; Lu W; Luo C
Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
[No Abstract] [Full Text] [Related]
16. Bromodomain inhibitors and cancer therapy: From structures to applications.
Pérez-Salvia M; Esteller M
Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
[TBL] [Abstract][Full Text] [Related]
17. GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
Watson RJ; Bamborough P; Barnett H; Chung CW; Davis R; Gordon L; Grandi P; Petretich M; Phillipou A; Prinjha RK; Rioja I; Soden P; Werner T; Demont EH
J Med Chem; 2020 Sep; 63(17):9045-9069. PubMed ID: 32691589
[TBL] [Abstract][Full Text] [Related]
18. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Hewings DS; Rooney TP; Jennings LE; Hay DA; Schofield CJ; Brennan PE; Knapp S; Conway SJ
J Med Chem; 2012 Nov; 55(22):9393-413. PubMed ID: 22924434
[TBL] [Abstract][Full Text] [Related]
19. Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors.
Zhang F; Ma S
Curr Drug Targets; 2018; 19(10):1148-1165. PubMed ID: 29189147
[TBL] [Abstract][Full Text] [Related]
20. Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells.
Li X; Wu Y; Tian G; Jiang Y; Liu Z; Meng X; Bao X; Feng L; Sun H; Deng H; Li XD
J Am Chem Soc; 2019 Jul; 141(29):11497-11505. PubMed ID: 31246451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]